IVRO Stock Overview
InVitro International develops test kits for non-animal testing applications in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InVitro International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.055 |
| 52 Week High | US$0.11 |
| 52 Week Low | US$0.028 |
| Beta | -0.74 |
| 1 Month Change | 5.70% |
| 3 Month Change | -8.83% |
| 1 Year Change | -32.47% |
| 3 Year Change | -36.47% |
| 5 Year Change | 9.40% |
| Change since IPO | -98.10% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IVRO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.5% | 1.4% | 1.2% |
| 1Y | -32.5% | -0.7% | 24.7% |
Return vs Industry: IVRO underperformed the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: IVRO underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| IVRO volatility | |
|---|---|
| IVRO Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVRO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IVRO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | n/a | Rich Ulmer | www.invitrointl.com |
InVitro International develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company also provides customized technology services for Irritection Assay System installation and testing process, and independent testing laboratory services for irritancy and corrosivity testing requirements, as well as consultation and assistance services.
InVitro International Fundamentals Summary
| IVRO fundamental statistics | |
|---|---|
| Market cap | US$1.24m |
| Earnings (TTM) | US$1.55k |
| Revenue (TTM) | US$792.63k |
798.1x
P/E Ratio1.6x
P/S RatioIs IVRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVRO income statement (TTM) | |
|---|---|
| Revenue | US$792.63k |
| Cost of Revenue | US$156.64k |
| Gross Profit | US$635.99k |
| Other Expenses | US$634.43k |
| Earnings | US$1.55k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.000069 |
| Gross Margin | 80.24% |
| Net Profit Margin | 0.20% |
| Debt/Equity Ratio | 0% |
How did IVRO perform over the long term?
See historical performance and comparison